Lawsuit Filed Over Fatal Heart Valve Defect
A widow alleges a defective Trifecta GT valve caused her husband's death in a case transferred to federal court.
Updated on Oct. 9, 2026 in Heart Disease
Amy Nachman filed a lawsuit on August 31, 2026, against Abbott Laboratories and St. Jude Medical. The complaint alleges that a manufacturing defect in the Trifecta GT heart valve led to the death of Alan Potash.
Why it matters
The litigation follows a 2023 recall of the devices after the FDA identified premature structural deterioration risks. Regulators reported that Trifecta prosthetics experienced early failure rates that were considered unacceptably high.
Between 2011 and 2023, the FDA received roughly 3,000 adverse event reports linked to Trifecta heart valves. These reports identified nearly 200 deaths associated with the implants.
The players
Amy Nachman
She is the plaintiff in the lawsuit filed against the medical device manufacturers.
Abbott Laboratories
This is a global healthcare company that acquired St. Jude Medical in 2017.
St. Jude Medical
This former independent device manufacturer was acquired by Abbott Laboratories and produced the Trifecta heart valve series.
Alan Potash
He was the husband of the plaintiff whose death is the subject of the product liability complaint.
The details
The lawsuit contends the Trifecta GT heart valve tore loose inside the patient. Surgeons discovered the structural damage when removing the device from Alan Potash.
Timeline
2011: Original Trifecta heart valve approved by FDA.
2016: Trifecta GT model approved by FDA.
2017: Abbott Laboratories acquired St. Jude Medical.
July 2023: Abbott recalled all Trifecta heart valves.
August 31, 2026: Lawsuit filed in Nebraska state court.
Health Landscape
This case follows the pattern set by the 2023 recall of Trifecta heart valves, which serves as the regulatory foundation for the current litigation. It highlights the long-term oversight challenges regarding prosthetic devices that exhibit premature structural failure.
Patients who received a Trifecta heart valve between 2011 and 2023 should maintain regular contact with their cardiologists to monitor for signs of early structural deterioration. The FDA recall notice advises those with these implants to discuss potential risks and monitoring protocols with their healthcare providers.
The takeaway
Patients implanted with recalled medical devices should keep comprehensive records of their surgical history and any adverse health symptoms. Regular follow-up appointments remain critical for identifying potential device failure before life-threatening complications arise.
Further reading
For more information on the management of valve conditions, visit the Heart Disease section.
Source note: This article includes information reported by AboutLawsuits.
